NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Christian R, Saavedra L, Gaynes BN, et al. Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Feb. (Future Research Needs Papers, No. 13.)
Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults [Internet].
Show detailsTable A-1Food and Drug Administration-approved first-generation antipsychotics
| Generic Name | Indications | Age Group for Which Approved |
|---|---|---|
| Chlorpromazine | Schizophrenia | Adults and children (1–12 years) |
| Bipolar disorder (mania) | ||
| Hyperactivity | ||
| Severe behavioral problems | ||
| Droperidol | Agitation | Adults and children |
| Fluphenazine | Psychotic disorders | Adults |
| Haloperidol | Schizophrenia | Adults |
| Tourette syndrome | ||
| Hyperactivity | ||
| Severe childhood behavioral problems | ||
| Loxapine | Schizophrenia | Adults and children ≥12 years |
| Perphenazine | Schizophrenia | Adults and children ≥12 years |
| Pimozide | Tourette syndrome | Adults and children ≥12 years |
| Prochlorperazine | Schizophrenia | Adults and children >2 years and >20 pounds |
| Generalized nonpsychotic anxiety | Adults | |
| Thiothixene | Schizophrenia | Adults and children ≥12 years |
| Thioridazine | Schizophrenia | Adults and children |
| Trifluoperazine | Schizophrenia | Adults and children ≥6 years |
| Generalized nonpsychotic anxiety | Adults |
Abbreviations: NA=not applicable
Table A-2Food and Drug Administration-approved second-generation antipsychotics
| Generic Name | Indications | Age Group for Which Approved |
|---|---|---|
| Aripiprazole | Schizophrenia | Adults and adolescents (13–17 years) |
| Bipolar disorder (manic/mixed) monotherapy or adjunctive to lithium or valproate | Adults and children (10–17 years) | |
| Adjunctive treatment of major depressive disorder | Adults | |
| Irritability Associated with autistic disorder | Children (6–17 years) | |
| Acute treatment of agitation | Adults | |
| Asenapine | Acute schizophrenia | Adults |
| Bipolar disorder type 1 (manic/mixed) | ||
| Clozapine | Treatment resistant schizophrenia | Adults |
| Reduce the risk of suicidal behavior in younger patients with schizophrenia. | ||
| Iloperidone | Acute schizophrenia | Adults |
| Olanzapine | Schizophrenia Bipolar disorder (manic/mixed) | Adults and adolescents (13–17 years) |
| Bipolar disorder | Adults | |
| Treatment resistant depression | ||
| Agitation associated with schizophrenia and bipolar I mania | ||
| Paliperidone | Schizophrenia Schizoaffective disorder | Adults |
| Quetiapine | Schizophrenia | Adults and adolescents (13–17 years) |
| Bipolar disorder (acute manic) | Adults, children, and adolescents (10–17 years) | |
| Bipolar disorder (depression) | Adults | |
| Bipolar disorder (maintenance) | ||
| Adjunctive therapy for major depressive disorder | ||
| Risperidone | Schizophrenia | Adults and adolescents (13–17 years) |
| Bipolar disorder (manic/mixed) | Adults and adolescents (10–17 years) | |
| Irritability associated with autism | Children (5–16 years) | |
| Ziprasidone | Schizophrenia | Adults |
| Bipolar disorder (manic/mixed) | ||
| Bipolar disorder (maintenance) | ||
| Acute agitation in patients with schizophrenia |
Abbreviations: NA, not applicable
- Tables of FDA-Approved Indications for First- and Second-Generation Antipsychoti...Tables of FDA-Approved Indications for First- and Second-Generation Antipsychotics - Future Research Needs for First- and Second-Generation Antipsychotics for Children and Young Adults
Your browsing activity is empty.
Activity recording is turned off.
See more...